Literature DB >> 10913875

Clostridium perfringens epsilon toxin causes excessive release of glutamate in the mouse hippocampus.

O Miyamoto1, K Sumitani, T Nakamura, S Yamagami, S Miyata, T Itano, T Negi, A Okabe.   

Abstract

The mechanism of neurotoxicity of Clostridium perfringens epsilon toxin to the mouse brain was investigated. Intravenous injection in mice with the toxin caused seizure and excited hippocampal neurons. Microdialysis revealed that epsilon toxin induced excessive glutamate release in the hippocampus. Both the seizure and glutamate release were attenuated by prior injection with riluzole, an inhibitor of pre-synaptic glutamate release, suggesting that this toxin enhances glutamate efflux, leading to seizure and hippocampal neuronal damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913875     DOI: 10.1111/j.1574-6968.2000.tb09215.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  21 in total

1.  Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance.

Authors:  Eiji Tamai; Tetsuya Ishida; Shigeru Miyata; Osamu Matsushita; Hirofumi Suda; Shoji Kobayashi; Hiroshi Sonobe; Akinobu Okabe
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

2.  Identification of tyrosine 71 as a critical residue for the cytotoxic activity of Clostridium perfringens epsilon toxin towards MDCK cells.

Authors:  Zhigang Jiang; Jitao Chang; Fang Wang; Li Yu
Journal:  J Microbiol       Date:  2015-01-28       Impact factor: 3.422

3.  The Cytotoxicity of Epsilon Toxin from Clostridium perfringens on Lymphocytes Is Mediated by MAL Protein Expression.

Authors:  Marta Blanch; Jonatan Dorca-Arévalo; Anna Not; Mercè Cases; Inmaculada Gómez de Aranda; Antonio Martínez-Yélamos; Sergio Martínez-Yélamos; Carles Solsona; Juan Blasi
Journal:  Mol Cell Biol       Date:  2018-09-14       Impact factor: 4.272

Review 4.  Bacterial Signaling to the Nervous System through Toxins and Metabolites.

Authors:  Nicole J Yang; Isaac M Chiu
Journal:  J Mol Biol       Date:  2017-01-06       Impact factor: 5.469

5.  Clinico-pathological findings of Clostridium perfringens type D enterotoxaemia in goats and its hemolytic activity in different erythrocytes.

Authors:  A Ali Nasir; M Younus; A Rashid; S Abdul Khaliq; E Khan; S H Shah; A Aslam; M A Ghumman; M H Joiya
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

Review 6.  Animal models to study the pathogenesis of human and animal Clostridium perfringens infections.

Authors:  Francisco A Uzal; Bruce A McClane; Jackie K Cheung; James Theoret; Jorge P Garcia; Robert J Moore; Julian I Rood
Journal:  Vet Microbiol       Date:  2015-02-25       Impact factor: 3.293

7.  Clostridium perfringens epsilon toxin targets granule cells in the mouse cerebellum and stimulates glutamate release.

Authors:  Etienne Lonchamp; Jean-Luc Dupont; Laetitia Wioland; Raphaël Courjaret; Corinne Mbebi-Liegeois; Emmanuel Jover; Frédéric Doussau; Michel R Popoff; Jean-Louis Bossu; Jean de Barry; Bernard Poulain
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

8.  Development and application of an oral challenge mouse model for studying Clostridium perfringens type D infection.

Authors:  Mariano E Fernandez-Miyakawa; Sameera Sayeed; Derek J Fisher; Rachael Poon; Vicki Adams; Julian I Rood; Bruce A McClane; Julian Saputo; Francisco A Uzal
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

Review 9.  Pathogenesis and diagnostic features of brain and ophthalmic damage produced by Clostridium perfringens type D epsilon toxin.

Authors:  John W Finnie; Mauricio A Navarro; Francisco A Uzal
Journal:  J Vet Diagn Invest       Date:  2020-01-20       Impact factor: 1.279

10.  Clostridium perfringens epsilon toxin increases the small intestinal permeability in mice and rats.

Authors:  Jorge Goldstein; Winston E Morris; César Fabián Loidl; Carla Tironi-Farinati; Carla Tironi-Farinatti; Bruce A McClane; Francisco A Uzal; Mariano E Fernandez Miyakawa
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.